Unique Technology/Candidates
Mediar Therapeutics is a clinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis and restore long-term organ function. The platform and pipeline are based on an emerging class of novel targets - fibrotic mediators - that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs.
Mediar’s approach offers a critical window to tackle later-stage fibrosis, which is among the hardest-to-treat conditions with little to no available therapeutic options. The company is currently advancing first-in-class antibodies to address fibrosis in several fibrotic indications including those in lung and liver with possibly future indications in renal and cardiac fibrosis.
Most Recent Funding
$85M Series A
- Novartis Venture Fund
- Sofinnova Partners
- Pfizer Ventures
- Mission BioCapital
- Gimv
- Pureos
- Bristol Myers Squibb
- Eli Lilly and Company
- Ono Venture Investment
- Mass General Brigham Ventures
Total: USD ~$105 raised
Current Clinical Focus
- Preparation for MTX-463 into phase 1 clinical development in 20214.
- Preparation for MTX-474 into phase 1 clinical development in 2024.
Therapeutic Modality
Monoclonal Antibodies
Therapeutic Area / Disease
Respiratory / Fibrotic disease
Hepatology / Fibrotic disease
Company Location
Cambridge, MA
